Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the Nanopatch™ microprojection array by Wan, Ying et al.
DEVELOPMENT OF STABILIZING FORMULATIONS OF A TRIVALENT INACTIVATED POLIOVIRUS 
VACCINE IN A DRIED STATE FOR DELIVERY IN THE NANOPATCHTM MICROPROJECTION ARRAY  
 
Ying Wan, University of Kansa 
ywan@ku.edu 
John M. Hickey, University of Kansa 
Christopher Bird, University of Kansa  
Katey Witham, Vaxxas Pty Ltd 
Paul Fahey, Vaxxas Pty Ltd 
Angus Forster, Vaxxas Pty Ltd 
Sangeeta B. Joshi, University of Kansa 
David B. Volkin, University of Kansa 
 
 
Key Words: Poliovirus, vaccine, formulation, stability, NanopatchTM 
 
The worldwide switch to inactivated polio vaccines (IPV) is a key component of the overall strategy to achieve 
and maintain global polio eradication. To this end, new IPV vaccine delivery systems may enhance patient 
convenience and compliance. In this work, we examine NanopatchTM (a solid, polymer micro-projection array) 
which offers potential advantages over standard needle/syringe administration including intradermal delivery 
and reduced antigen doses. Using trivalent IPV (tIPV) and a purpose-built evaporative dry-down system, 
candidate tIPV formulations were developed to stabilize tIPV during the drying process and upon storage. 
Identifying conditions to minimize tIPV potency losses during rehydration and potency testing was a critical first 
step. Various classes and types of pharmaceutical excipients (~50 total) were then evaluated to mitigate 
potency losses (measured through D-antigen ELISAs for IPV1, IPV2, and IPV3) during drying and storage. 
Various concentrations and combinations of stabilizing additives were optimized in terms of tIPV potency 
retention, and two candidate tIPV formulations containing a cyclodextrin and a reducing agent (e.g., 
glutathione), maintained ≥80% D-antigen potency during drying and subsequent storage for 4 weeks at 4˚C, and 
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